Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

A Case of Iatrogenic Cushing Syndrome Secondary to Application of Topical Corticosteroids.

Sardesai VR, Dhamale SS, Hegde SS.

Indian Dermatol Online J. 2019 Jul-Aug;10(4):476-478. doi: 10.4103/idoj.IDOJ_374_18. No abstract available.

2.

The active site of the Mycobacterium tuberculosis branched-chain amino acid biosynthesis enzyme dihydroxyacid dehydratase contains a 2Fe-2S cluster.

Bashiri G, Grove TL, Hegde SS, Lagautriere T, Gerfen GJ, Almo SC, Squire CJ, Blanchard JS, Baker EN.

J Biol Chem. 2019 Aug 30;294(35):13158-13170. doi: 10.1074/jbc.RA119.009498. Epub 2019 Jul 16.

PMID:
31315931
3.

Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).

McKinnell RM, Fatheree P, Choi SK, Gendron R, Jendza K, Olson Blair B, Budman J, Hill CM, Hegde LG, Yu C, McConn D, Hegde SS, Marquess DG, Klein U.

ACS Med Chem Lett. 2018 Dec 3;10(1):86-91. doi: 10.1021/acsmedchemlett.8b00462. eCollection 2019 Jan 10.

PMID:
30655952
4.

Identification of bone-specific alkaline phosphatase in saliva and its correlation with skeletal age.

Hegde SS, Revankar AV, Patil AK.

Indian J Dent Res. 2018 Nov-Dec;29(6):721-725. doi: 10.4103/ijdr.IJDR_298_15.

5.

Quantitative CT and 19F-MRI tracking of perfluorinated encapsulated mesenchymal stem cells to assess graft immunorejection.

Wang G, Fu Y, Shea SM, Hegde SS, Kraitchman DL.

MAGMA. 2019 Feb;32(1):147-156. doi: 10.1007/s10334-018-0728-2. Epub 2018 Dec 10.

PMID:
30535540
6.

Clinical and Histopathological Analysis of Odontogenic Tumors in Institution-A 10 Years Retrospective Study.

Mehngi R, Rajendra K, Bhagwat P, Hegde SS, Sah D, Rathod VS.

J Contemp Dent Pract. 2018 Oct 1;19(10):1288-1292.

PMID:
30498188
7.

Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.

Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR.

Pharmacol Res Perspect. 2018 Apr 30;6(3):e00400. doi: 10.1002/prp2.400. eCollection 2018 Jun.

8.

High-resolution and accelerated multi-parametric mapping with automated characterization of vessel disease using intravascular MRI.

Wang G, Zhang Y, Hegde SS, Bottomley PA.

J Cardiovasc Magn Reson. 2017 Nov 20;19(1):89. doi: 10.1186/s12968-017-0399-6.

9.

Highly Accelerated, Intravascular T1, T2, and Proton Density Mapping with Linear Algebraic Modeling and Sensitivity Profile Correction at 3T.

Wang G, Zhang Y, Hegde SS, Bottomley PA.

Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib. 2016 May;24:2829.

10.

Pauci-immune crescentic glomerulonephritis associated with use of trimethoprim-sulfamethoxazole.

Hegde SS, Bijol V, Jaber BL.

CEN Case Rep. 2016 Nov;5(2):188-191. doi: 10.1007/s13730-016-0222-5. Epub 2016 Jun 7.

11.

Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4+ T Cells.

Johnson AJ, Kennedy SC, Lindestam Arlehamn CS, Goldberg MF, Saini NK, Xu J, Paul S, Hegde SS, Blanchard JS, Chan J, Jacobs WR Jr, Sette A, Porcelli SA.

Infect Immun. 2017 Mar 23;85(4). pii: e01023-16. doi: 10.1128/IAI.01023-16. Print 2017 Apr.

12.

Automated classification of vessel disease based on high-resolution intravascular multi-parametric mapping MRI.

Wang G, Erturk MA, Hegde SS, Bottomley PA.

Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib. 2015 May-Jun;2015:1659. No abstract available.

13.

Are blood vessels a target to treat lower urinary tract dysfunction?

Michel MC, Chess-Williams R, Hegde SS.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jul;388(7):687-94. doi: 10.1007/s00210-015-1137-y. Epub 2015 May 31.

PMID:
26026700
14.

A combined interventional high-resolution targeted ablation, thermometry and imaging probe.

Erturk MA, Hegde SS, Bottomley PA.

Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib. 2015 May-Jun;23:1645. No abstract available.

16.

Comparitive angiographic profile in diabetic and non-diabetic patients with acute coronary syndrome.

Hegde SS, Mallesh P, Yeli SM, Gadad VM, M GP.

J Clin Diagn Res. 2014 Sep;8(9):MC07-10. doi: 10.7860/JCDR/2014/9072.4851. Epub 2014 Sep 20.

17.

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.

Hegde SS, Janc JW.

Expert Rev Anti Infect Ther. 2014 Dec;12(12):1463-75. doi: 10.1586/14787210.2014.979789. Review.

PMID:
25382700
19.

Acceleration and motion-correction techniques for high-resolution intravascular MRI.

Hegde SS, Zhang Y, Bottomley PA.

Magn Reson Med. 2015 Aug;74(2):452-61. doi: 10.1002/mrm.25436. Epub 2014 Aug 27.

20.

Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.

Hegde SS, Hughes AD, Chen Y, Steinfeld T, Jasper JR, Lee TW, McNamara A, Martin WJ, Pulido-Rios MT, Mammen M.

J Pharmacol Exp Ther. 2014 Oct;351(1):190-9. doi: 10.1124/jpet.114.216861. Epub 2014 Aug 6.

PMID:
25100753
21.

Bilateral primary angiosarcoma of the breast.

Keshav P, Hegde SS.

Case Rep Surg. 2013;2013:139276. doi: 10.1155/2013/139276. Epub 2013 Sep 30.

22.

In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS.

J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. doi: 10.1124/jpet.113.203554. Epub 2013 May 17.

PMID:
23685545
23.

The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.

Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD, Hegde SS, Beattie DT.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):471-8. doi: 10.1007/s00210-013-0844-5. Epub 2013 Mar 13.

PMID:
23512167
24.

A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.

Long DD, Frieman B, Hegde SS, Hill CM, Jiang L, Kintz S, Marquess DG, Purkey H, Shaw JP, Steinfeld T, Wilson MS, Wrench K.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):939-43. doi: 10.1016/j.bmcl.2012.12.058. Epub 2012 Dec 22.

PMID:
23317571
25.

3T intravascular MRI, IVUS and OCT: A study in contrast.

Hegde SS, Weiss CR, Erturk MA, Bottomley PA.

Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib. 2013;21:1833. No abstract available.

26.

Accelerated, motion-corrected high-resolution intravascular MRI at 3T.

Hegde SS, Zhang Y, Bottomley PA.

Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib. 2013;21:0473-473. No abstract available.

27.

Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β(2)-adrenoceptor agonist (MABA).

McNamara A, Steinfeld T, Pulido-Rios MT, Stangeland E, Hegde SS, Mammen M, Martin WJ.

Pulm Pharmacol Ther. 2012 Oct;25(5):357-63. doi: 10.1016/j.pupt.2012.06.007. Epub 2012 Jul 2.

PMID:
22766316
28.

Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.

Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL.

Antimicrob Agents Chemother. 2012 Apr;56(4):2062-6. doi: 10.1128/AAC.00383-11. Epub 2012 Jan 17.

29.

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12.

30.

Reversible acetylation and inactivation of Mycobacterium tuberculosis acetyl-CoA synthetase is dependent on cAMP.

Xu H, Hegde SS, Blanchard JS.

Biochemistry. 2011 Jul 5;50(26):5883-92. doi: 10.1021/bi200156t. Epub 2011 Jun 10.

31.

Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor.

Vetting MW, Hegde SS, Wang M, Jacoby GA, Hooper DC, Blanchard JS.

J Biol Chem. 2011 Jul 15;286(28):25265-73. doi: 10.1074/jbc.M111.226936. Epub 2011 May 19.

32.

Pentapeptide-repeat proteins that act as topoisomerase poison resistance factors have a common dimer interface.

Vetting MW, Hegde SS, Zhang Y, Blanchard JS.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Mar 1;67(Pt 3):296-302. doi: 10.1107/S1744309110053315. Epub 2011 Feb 18.

33.

Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.

Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.

J Cardiovasc Pharmacol. 2011 Apr;57(4):495-504. doi: 10.1097/FJC.0b013e318210fc7e.

PMID:
21297495
34.

Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor.

Hegde SS, Vetting MW, Mitchenall LA, Maxwell A, Blanchard JS.

Antimicrob Agents Chemother. 2011 Jan;55(1):110-7. doi: 10.1128/AAC.01158-10. Epub 2010 Oct 11.

35.

Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.

Seiner DR, Hegde SS, Blanchard JS.

Biochemistry. 2010 Nov 9;49(44):9613-9. doi: 10.1021/bi1011157.

36.

The structure and mechanism of the Mycobacterium tuberculosis cyclodityrosine synthetase.

Vetting MW, Hegde SS, Blanchard JS.

Nat Chem Biol. 2010 Nov;6(11):797-9. doi: 10.1038/nchembio.440. Epub 2010 Sep 19.

37.

Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents.

McNamara A, Pulido-Rios MT, Hegde SS, Martin WJ.

J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):89-95. doi: 10.1016/j.vascn.2010.05.016. Epub 2010 Jun 8.

PMID:
20594937
38.

In vitro isolated tissue functional muscarinic receptor assays.

Pulido-Rios MT, Steinfeld T, Armstrong S, Watson N, Choppin A, Eglen R, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 4:Unit 4.15. doi: 10.1002/0471141755.ph0415s48.

PMID:
22294371
39.

In vivo pharmacodynamic assays for M2 and M3 muscarinic receptors.

Armstrong S, Steinfeld T, Pulido-Rios MT, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 12:Unit 12.13. doi: 10.1002/0471141755.ph1213s48.

PMID:
22294364
40.

In vitro muscarinic receptor radioligand-binding assays.

Steinfeld T, Pulido-Rios MT, Armstrong S, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 1:Unit 1.33. doi: 10.1002/0471141755.ph0133s48.

PMID:
22294363
41.

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.

Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.

J Antimicrob Chemother. 2010 Apr;65(4):725-8. doi: 10.1093/jac/dkq028. Epub 2010 Feb 5.

PMID:
20139142
42.

Freeman-Sheldon syndrome--prenatal and postnatal diagnosis.

Hegde SS, Shetty MS, Rama Murthy BS.

Indian J Pediatr. 2010 Feb;77(2):196-7. doi: 10.1007/s12098-009-0227-6. Epub 2009 Dec 11.

PMID:
20012803
43.

Crystallization of a pentapeptide-repeat protein by reductive cyclic pentylation of free amines with glutaraldehyde.

Vetting MW, Hegde SS, Blanchard JS.

Acta Crystallogr D Biol Crystallogr. 2009 May;65(Pt 5):462-9. doi: 10.1107/S0907444909008324. Epub 2009 Apr 18.

44.

Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

Long DD, Aggen JB, Chinn J, Choi SK, Christensen BG, Fatheree PR, Green D, Hegde SS, Judice JK, Kaniga K, Krause KM, Leadbetter M, Linsell MS, Marquess DG, Moran EJ, Nodwell MB, Pace JL, Trapp SG, Turner SD.

J Antibiot (Tokyo). 2008 Oct;61(10):603-14. doi: 10.1038/ja.2008.80.

PMID:
19168974
45.

A multivalent approach to drug discovery for novel antibiotics.

Long DD, Aggen JB, Christensen BG, Judice JK, Hegde SS, Kaniga K, Krause KM, Linsell MS, Moran EJ, Pace JL.

J Antibiot (Tokyo). 2008 Oct;61(10):595-602. doi: 10.1038/ja.2008.79.

PMID:
19168973
46.

Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.

McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.

Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. doi: 10.1016/j.ejphar.2008.12.043. Epub 2009 Jan 10.

PMID:
19168050
47.

Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.

Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM.

J Antimicrob Chemother. 2009 Apr;63(4):763-6. doi: 10.1093/jac/dkp001. Epub 2009 Jan 20.

PMID:
19155225
48.

The management of renal matrix calculi: a single-centre experience over 5 years.

Shah HN, Kharodawala S, Sodha HS, Khandkar AA, Hegde SS, Bansal MB.

BJU Int. 2009 Mar;103(6):810-4. doi: 10.1111/j.1464-410X.2008.08065.x. Epub 2008 Sep 8.

49.

Mechanistic and structural analysis of aminoglycoside N-acetyltransferase AAC(6')-Ib and its bifunctional, fluoroquinolone-active AAC(6')-Ib-cr variant.

Vetting MW, Park CH, Hegde SS, Jacoby GA, Hooper DC, Blanchard JS.

Biochemistry. 2008 Sep 16;47(37):9825-35. doi: 10.1021/bi800664x. Epub 2008 Aug 19.

50.

A randomized trial evaluating type of nephrostomy drainage after percutaneous nephrolithotomy: small bore v tubeless.

Shah HN, Sodha HS, Khandkar AA, Kharodawala S, Hegde SS, Bansal MB.

J Endourol. 2008 Jul;22(7):1433-9. doi: 10.1089/end.2007.0350.

PMID:
18690809

Supplemental Content

Loading ...
Support Center